COMPANY
Rebel Medicine Inc
Timeline
- Trial start Phase 2: Sciatic Nerve Block With ALX006 in Subjects Undergoing Bunionectomy source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07574385 | Sciatic Nerve Block With ALX006 in Subjects Undergoing Bunionectomy | Phase 2 | Recruiting | Mar 10, 2026 | 2026-08 (estimated) |
NIH awards 3
- NIH award 1R43DA059315-01A1 FY2024: $295,921 awarded for that fiscal year; activity R43 (SBIR); PI DAVIS, BRETT; recipient as written: REBEL MEDICINE INC, Salt Lake City, UT. Extending duration of an injectable long- source ↗
- NIH award 3R43GM142413-01A1S1 FY2022: $6,500 awarded for that fiscal year; activity R43 (SBIR); PI DAVIS, BRETT; recipient as written: REBEL MEDICINE INC, Salt Lake City, UT. Development of a novel sustained release source ↗
- NIH award 1R43GM142413-01A1 FY2021: $256,551 awarded for that fiscal year; activity R43 (SBIR); PI DAVIS, BRETT; recipient as written: REBEL MEDICINE INC, Salt Lake City, UT. Development of a novel sustained release source ↗